Bolivia Medical Device Regulation 2026: ATT Type Approval and the Updated Wireless Equipment List

1. Key takeaways

The Bolivian telecommunications and transport regulator (ATT) published its list of telecommunications equipment subject to approval on 28 January 2026 and updated it on 25 February 2026, adding categories including LoRaWAN, RFID, short range devices (SRD) and FM/AM receivers. The two versions are divided by 25 February 2026: submissions made before that date are examined under the old list, submissions after it under the new one. ATT has stated that it will no longer issue a declaration that approval is not required. The institutional basis is Resolución ATT-DJ-RAR-TL LP 539/2024. Medical telemetry systems already fall within the regulated description. GRZAN’s assessment is that this is the change with the most direct effect on device companies in Bolivia in the past two years, and because it sits outside the AGEMED procedure, it is the one most easily omitted from a plan.

The structural reason for the omission is jurisdictional rather than technical. Device teams are trained to look at the health authority, and the ATT obligation belongs to a different regulator with a different legal basis, a different document set and a different queue. A project plan organised around AGEMED sections will not contain a line for it, and a plan that does not contain a line for it will not schedule it.

For any device with a radio interface, the consequence is that the Bolivian path has two regulators in sequence rather than one, and the import step sits behind both of them.

2. Legal basis

Resolución ATT-DJ-RAR-TL LP 539/2024 establishes the approval regime and is the instrument to cite when corresponding with ATT; the equipment list published on 28 January 2026 and updated on 25 February 2026 determines whether a given product falls inside that regime. Section 2.9 of the manual touches the same subject from the health side, and Form 011 governs the customs clearance authorisation at the point where the two regimes meet the border. The practical point is that the health framework acknowledges the existence of the telecom requirement without discharging it: a device can hold a valid AGEMED registration and still be unable to clear customs because the ATT approval has not been obtained.

3. Expert insights

Insight 1: the withdrawal of the no-approval declaration changes the structure of the argument. Previously a company could demonstrate with a single letter that a product fell outside the scope of approval. ATT no longer provides that document, which means that anything inside the list can only be approved, with no exemption route. For a company whose portfolio contains several wireless stock-keeping units, the cost effect is multiplicative rather than additive, because each unit requires its own approval file and its own fee.

Insight 2: medical telemetry systems are expressly named. This directly covers categories such as remote monitoring, wearable follow-up and wireless infusion pump management. GRZAN recommends making the question of whether a product contains a wireless module a mandatory screening item at the project initiation stage, rather than leaving it to the technical documentation stage, because by then the hardware configuration is fixed and the schedule has already been built around a single regulator.

Insight 3: approval is linked to customs clearance and therefore sits on the critical path. ATT type approval is a precondition for import. Because it is handled by a different authority from the AGEMED sanitary registration, GRZAN’s scheduling principle is to start both in parallel and converge on clearance as the shared end point. On a practical estimate the ATT step takes approximately 7 to 12 weeks, which is why it has to start at the same time as the sanitary registration. That period is an industry experience value, not an officially published time limit.

Insight 4: the list version determines the assessment criteria, so the submission date is a substantive decision. Because submissions before 25 February 2026 are examined against the old list and later ones against the new list, the date on which a file is lodged can change which categories it must satisfy. A company planning a submission around that boundary should confirm the position with ATT rather than assume that filing earlier is always better, since the earlier route may not cover a product that the new list addresses.

4. Practical recommendations

1. Run a mandatory wireless screening at project initiation: Bluetooth, Wi-Fi, cellular, LoRa and RFID should all be entered as approval tasks rather than treated as product features.
2. Reserve 7 to 12 weeks and run the approval in parallel with the sanitary registration (practical estimate).
3. Confirm the applicability of the current list with ATT before freezing the technical design, so that a mid-project revision does not force a second approval.
4. Enter the obligation in the project plan as a separate workstream with its own owner, so that it is not lost inside the AGEMED checklist.

5. Verification checklist

• □ The product contains no radio transmitting or receiving module, or the module has been identified
• □ Applicability has been checked against the list of 25 February 2026
• □ The list version applicable at the intended submission date has been established
• □ ATT approval has been started in parallel with the sanitary registration
• □ It has been confirmed that the no-approval declaration route is not available

Regulatory information verified as of October 29, 2026.

GRZAN supports medical device manufacturers, importers and authorised representatives with registration in Bolivia, including screening of wireless functions against the ATT equipment list, coordination of ATT type approval with the AGEMED sanitary registration, and sequencing of both against the customs clearance step. For assistance with a wireless device or a parallel approval plan for Bolivia, contact the GRZAN regulatory team at info@grzanglobal.com.

GRZAN applies a writing standard of conclusions first, traceable sources and verifiable figures to its regulatory publications, and follows the practice of AGEMED, ATT and the other authorities cited in this series as it develops. For a market access plan that places telecom approval on the same timeline as health registration, the team welcomes your enquiry.